Profits fell by a third at Johnson & Johnson’s Janssen unit in Cork as sales fell and it made a €46.9 million provision for personal injury claims relating to products in 2018. Janssen Pharmaceutical Sciences Unlimited Company reported profits of €205 million on sales of €605 millions – 20 per cent lower than the turnover of €755 million reported in 2017. In accounts just filed at Companies Office, Janssen directors confirm the company received personal injury claims relating to the anti psychotic drug, Risperdal and related products sold by the company. The €46.9 million provision in 2018 follows a provision of €48.2 million in 2017. Separate accounts for another Cork based Janssen unit, Janssen Sciences Ireland Unlimited show that the company paid out a dividend of €6.98 billion in 2018 as pre-tax profits rose 22 per cent to €2.7 billion.

Source: The Irish Times January 02, 2020 18:33 UTC